Becton Dickinson and Co (NYSE:BDX) – Analysts at Jefferies Group cut their Q2 2018 EPS estimates for Becton Dickinson and in a research report issued on Tuesday. Jefferies Group analyst B. Couillard now forecasts that the medical instruments supplier will earn $2.56 per share for the quarter, down from their previous forecast of $2.60. Jefferies Group also issued estimates for Becton Dickinson and’s Q3 2018 earnings at $2.81 EPS, Q1 2019 earnings at $3.05 EPS, Q3 2019 earnings at $3.22 EPS and Q4 2019 earnings at $3.33 EPS.

A number of other research analysts have also weighed in on the company. Morgan Stanley increased their price objective on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday. Piper Jaffray Companies reissued an “overweight” rating and issued a $260.00 price objective (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price objective on the stock in a report on Friday, January 19th. Bank of America reissued a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a report on Friday, January 19th. Finally, Citigroup raised Becton Dickinson and from a “sell” rating to a “neutral” rating in a report on Friday, January 5th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus price target of $237.27.

Becton Dickinson and (NYSE:BDX) opened at $217.14 on Friday. The company has a quick ratio of 5.03, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $51,160.00, a PE ratio of 165.76, a PEG ratio of 1.45 and a beta of 1.12. Becton Dickinson and has a 1-year low of $175.66 and a 1-year high of $248.39.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.33 earnings per share.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in Becton Dickinson and by 6.0% during the fourth quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock worth $4,026,750,000 after acquiring an additional 1,071,288 shares during the period. Vanguard Group Inc. grew its holdings in Becton Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after acquiring an additional 1,353,780 shares during the period. State Street Corp grew its holdings in Becton Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after acquiring an additional 342,873 shares during the period. Northern Trust Corp grew its holdings in Becton Dickinson and by 4.0% during the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after acquiring an additional 106,966 shares during the period. Finally, Fundsmith LLP grew its holdings in Becton Dickinson and by 0.3% during the second quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock worth $449,258,000 after acquiring an additional 5,977 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.38%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is 229.01%.

ILLEGAL ACTIVITY WARNING: “Q2 2018 EPS Estimates for Becton Dickinson and Co Decreased by Jefferies Group (BDX)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/02/11/q2-2018-eps-estimates-for-becton-dickinson-and-co-decreased-by-jefferies-group-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.